Sanofi acquires U.S. biotech Principia BiopharmaSanofi announced the acquisition of U.S. biotech Principia Biopharma, for $3.68 billion (€3.10 billion) (APMHE 68559), boosting its capabilities in the field of multiple sclerosis, Les Echos (p13) and Le Figaro (p19) reported on Tuesday.
J&J to acquire Momenta for $6.5 billionJohnson & Johnson (J&J) will buy U.S. biotech Momenta Pharmaceuticals, specialised in autoimmune diseases, for $6.5 billion (€5.4 billions) (APMHE 68591), les Echos (p11) and Le Figaro (p21) reported on Thursday.
Roche and Regeneron team-up against Covid-19Roche and Regeneron announced that they will join forces in the fight against Covid-19 (APMHE 68587), reported Les Echos (p14) on Thursday.
$9.4 billion raised by biotechs since JanuaryBiotech company initial public offerings (IPOs) have raised a record amount of $9.4 billion on the U.S. stock market since the beginning of the year, said Les Echos on Monday (p21).
Three Covid-19 vaccines under testing in IndiaThree Covid-19 vaccines are being tested in India by Zydus Cadila, Bharat Biotech International and Serum Institute of India, Les Echos (p5) et l’Humanité (p3) reported on Tuesday.
Mexico and Argentina intend to provide vaccines to South AmericaMexico and Argentina are teaming up with AstraZeneca and the University of Oxford to provide the necessary production for South America, L'Humanité reported on Tuesday (p2-3).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.